C3L-02951
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 61.60711841
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- ANGIOGENESIS+0.500
- INTERFERON_ALPHA_RESPONSE+0.470
- WNT_BETA_CATENIN_SIGNALING+0.440
- HYPOXIA+0.420
- INFLAMMATORY_RESPONSE+0.420
- TNFA_SIGNALING_VIA_NFKB+0.410
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- COAGULATION+0.350
Top 10 suppressed
- PROTEIN_SECRETION-0.400
- PANCREAS_BETA_CELLS-0.130
- MYC_TARGETS_V1-0.090
- ANDROGEN_RESPONSE-0.050
- HEME_METABOLISM-0.040
- SPERMATOGENESIS-0.030
- MITOTIC_SPINDLE-0.020
- TGF_BETA_SIGNALING-0.020
- ADIPOGENESIS+0.000
- UV_RESPONSE_DN+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R303 | — | — | 0.901 |
| 2 | BS_4T0HPZDC | Posterior Fossa Ependymoma | — | 0.897 |
| 3 | BS_KXMYBQ6N | Spinal Cord Ependymoma | — | 0.893 |
| 4 | TCGA-43-6773-01A-41R-1949-07 | — | cohortSQ1 | 0.892 |
| 5 | BS_0QYS36NR | Ependymoma NOS | — | 0.884 |
| 6 | SRR11296840 | — | — | 0.881 |
| 7 | BS_KXMYBQ6N | EPN | EPN Tumor | 0.879 |
| 8 | 02faba9d-8eda-4967-995d-61a0c13b843c | — | — | 0.877 |
| 9 | BS_RXN5T5YT | Diffuse intrinsic pontine glioma | — | 0.872 |
| 10 | TCGA-DK-AA74-01A-11R-A39I-07 | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.440 | Inavolisib | — uncovered |
| HYPOXIA | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |